{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:20:27Z","timestamp":1776288027870,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.urolonc.2024.01.032","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T12:23:45Z","timestamp":1709382225000},"page":"160.e1-160.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-3687","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieding","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.032_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.urolonc.2024.01.032_bib0003","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cancers11091355","article-title":"Current treatment options for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"Suppl 6","key":"10.1016\/j.urolonc.2024.01.032_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.2023.41.6_suppl.28","article-title":"Survival trends in de novo metastatic prostate cancer: SEER and Veterans Affairs comparison","volume":"41","author":"Schoen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.01.032_bib0005","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.3390\/cancers12102855","article-title":"Epidemiological characteristics and survival in patients with de novo metastatic prostate cancer","volume":"12","author":"Cattrini","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0006","unstructured":"National Comprehensive Cancer Network. Prostate cancer guideline (version 1.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf; 2023 Accessed January 26, 2023."},{"issue":"14","key":"10.1016\/j.urolonc.2024.01.032_bib0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.032_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.01.032_bib0009","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"L\u00f8vf","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0010","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"issue":"7547","key":"10.1016\/j.urolonc.2024.01.032_bib0011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0012","unstructured":"National Cancer Institute. Overview of the SEER program, https:\/\/seer.cancer.gov\/about\/overview.html; 2023 Accessed April 22, 2023."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0013","unstructured":"National Cancer Institute. PSA values and SEER data, https:\/\/seer.cancer.gov\/data\/psa-values.html; 2023 Accessed November 12, 2023."},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0014","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/nar\/gkg034","article-title":"STRING: a database of predicted functional associations between proteins","volume":"31","author":"von Mering","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2407-7-64","article-title":"Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process","volume":"7","author":"Chandran","year":"2007","journal-title":"BMC Cancer."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0016","unstructured":"The human protein atlas. Pathology of HERV-FRD, https:\/\/www.proteinatlas.org\/ENSG00000244476-ERVFRD-1\/pathology; 2023 Accessed December 24, 2023]."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0017","unstructured":"The human protein atlas. Pathology of NUDT12, https:\/\/www.proteinatlas.org\/ENSG00000112874-NUDT12\/pathology; 2023 Accessed December 24, 2023]."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0018","unstructured":"The human protein atlas. Pathology of FAM63A, https:\/\/www.proteinatlas.org\/ENSG00000143409-MINDY1\/pathology; 2023 Accessed December 24, 2023]."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0019","unstructured":"The human protein atlas. Pathology of SCGB3A1, https:\/\/www.proteinatlas.org\/ENSG00000161055-SCGB3A1\/pathology; 2023 Accessed December 24, 2023]."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0020","unstructured":"The human protein atlas. Pathology of CEACAM6, https:\/\/www.proteinatlas.org\/ENSG00000086548-CEACAM6\/pathology; 2023 Accessed December 24, 2023]."},{"key":"10.1016\/j.urolonc.2024.01.032_bib0021","unstructured":"The human protein atlas. Pathology of SFTPB, https:\/\/www.proteinatlas.org\/ENSG00000168878-SFTPB\/pathology; 2023 Accessed December 24, 2023]."},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.032_bib0022","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.032_bib0023","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clgc.2019.03.020","article-title":"Prognostic significance of sites of visceral metastatic disease in prostate cancer: a population-based study of 12,180 patients","volume":"17","author":"Budnik","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"issue":"Suppl 6","key":"10.1016\/j.urolonc.2024.01.032_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2023.41.6_suppl.269","article-title":"Survival patterns based on site-specific visceral metastasis in patients with metastatic prostate cancer: are outcomes of visceral metastases the same?","volume":"41","author":"Ahmed","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2024.01.032_bib0026","doi-asserted-by":"crossref","first-page":"9796","DOI":"10.1073\/pnas.171138398","article-title":"HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells","volume":"98","author":"Krop","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","article-title":"Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states","volume":"13","author":"Song","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.urolonc.2024.01.032_bib0028","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1541-7786.489.2.9","article-title":"Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types","volume":"2","author":"Krop","year":"2004","journal-title":"Mol Cancer Res"},{"issue":"19","key":"10.1016\/j.urolonc.2024.01.032_bib0029","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1158\/0008-5472.CAN-05-0420","article-title":"Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)","volume":"65","author":"Blumenthal","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-7-2","article-title":"Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers","volume":"7","author":"Blumenthal","year":"2007","journal-title":"BMC Cancer."},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.032_bib0031","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000360649","article-title":"The molecular era of surfactant biology","volume":"105","author":"Whitsett","year":"2014","journal-title":"Neonatology"},{"issue":"12","key":"10.1016\/j.urolonc.2024.01.032_bib0032","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1096\/fj.14-254862","article-title":"The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling","volume":"28","author":"Lindskog","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1252905","article-title":"Endogenous retrovirus group FRD member 1 is a potential biomarker for prognosis and immunotherapy for kidney renal clear cell carcinoma","volume":"13","author":"Wen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0034","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s42003-021-02833-4","article-title":"Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer","volume":"4","author":"Namba","year":"2021","journal-title":"Commun Biol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.032_bib0035","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41589-019-0293-7","article-title":"Structural and mechanistic basis of mammalian Nudt12 RNA deNADding","volume":"15","author":"Grudzien-Nogalska","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"Suppl 7","key":"10.1016\/j.urolonc.2024.01.032_bib0036","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1538-7445.AM2023-4266","article-title":"Genomic landscape of prostate cancer: Bioinformatic analysis of TCGA PanCancer data by race and identification of key pathways and genes in PTEN mutation","volume":"83","author":"Arigbede","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0037","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.molcel.2016.05.009","article-title":"MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes","volume":"63","author":"Abdul Rehman","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.urolonc.2024.01.032_bib0038","doi-asserted-by":"crossref","first-page":"e14799","DOI":"10.7717\/peerj.14799","article-title":"Ubiquitin specific peptidases and prostate cancer","volume":"11","author":"Guo","year":"2023","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.urolonc.2024.01.032_bib0039","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.urolonc.2024.01.032_bib0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-022-00495-9","article-title":"Transcriptome subtyping of metastatic castration resistance prostate cancer (mCRPC) for the precision therapeutics: an in silico analysis","volume":"25","author":"Liang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2024.01.032_bib0041","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"issue":"49","key":"10.1016\/j.urolonc.2024.01.032_bib0042","doi-asserted-by":"crossref","first-page":"E4762","DOI":"10.1073\/pnas.1319948110","article-title":"Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets","volume":"110","author":"Drake","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.urolonc.2024.01.032_bib0043","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.01.032_bib0044","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat Rev Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T22:43:00Z","timestamp":1712875380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1078143924000486"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.032","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}